FindTrial
Sign In

Topical calcineurin inhibitors

DRUG4 trials

Sponsors

Sanofi

Conditions

Dermatitis AtopicNeurodermatitis

Phase 2

Long-Term Safety and Efficacy Evaluation of Amlitelimab in Participants of Previous Amlitelimab Moderate to Severe Atopic Dermatitis Clinical Trials
Enrolling by invitationNCT05492578
SanofiDermatitis Atopic
Start: 2022-08-22End: 2029-01-22Target: 1663Updated: 2026-03-19

Phase 3

Study of Dupilumab for the Treatment of Patients With Prurigo Nodularis, Inadequately Controlled on Topical Prescription Therapies or When Those Therapies Are Not Advisable (LIBERTY-PN PRIME)
CompletedNCT04183335
SanofiNeurodermatitis
Start: 2019-12-12End: 2022-02-03Updated: 2025-09-17
Study of Dupilumab for the Treatment of Patients With Prurigo Nodularis, Inadequately Controlled on Topical Prescription Therapies or When Those Therapies Are Not Advisable (PRIME2)
CompletedNCT04202679
SanofiNeurodermatitis
Start: 2020-01-16End: 2021-11-22Updated: 2025-09-17
A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis on Background Topical Corticosteroids
CompletedNCT06224348
SanofiDermatitis Atopic
Start: 2024-01-18End: 2025-11-01Updated: 2025-12-02

Related Papers

Dupilumab Improves Prurigo Activity and Severity in Patients with Prurigo Nodularis: A Post Hoc Analysis of Pooled Results from the PRIME and PRIME2 Trials
Dermatology and Therapy2026-04-01
Dupilumab Improves Daily Symptom Burden in Adult Patients with Prurigo Nodularis: Post Hoc Analysis from LIBERTY PN-PRIME and PRIME2 Studies.
2026-03-02
Dupilumab Reduces Pruritus in Clinically Distinct Dermatologic Diseases: Data from Clinical Trials on Atopic Dermatitis, Prurigo Nodularis, and Chronic Spontaneous Urticaria.
2025-11-22
Efficacy and Safety of Dupilumab in Adults with Prurigo Nodularis with or Without Atopic Comorbidities: A Subgroup Analysis from Two Randomized Phase III Clinical Trials.
2025-11-11
Interim Safety Results of Amlitelimab (anti-OX40 ligand antibody) in Participants With Moderate-to-Severe Atopic Dermatitis From the RIVER-AD Phase 2/3 Ongoing Open-Label Study
SKIN The Journal of Cutaneous Medicine2025-11-10
635 - Dupilumab is efficacious in patients with prurigo nodularis regardless of baseline lesion severity: pooled results from two phase 3 trials (LIBERTY-PN PRIME and PRIME2)
British Journal of Dermatology2024-08-011 citations
Worst Itch Numeric Rating Scale for Prurigo Nodularis: A Secondary Analysis of 2 Randomized Clinical Trials.
2024-08-011 citations
694 - Dupilumab improves itch and skin lesions in North American patients with prurigo nodularis: a subset analysis of the pooled results from two phase 3 trials (LIBERTY-PN PRIME and PRIME2)
British Journal of Dermatology2024-08-01
718 - Dupilumab reduces the number of lesions in adult patients with prurigo nodularis presenting with multiple lesion morphologies: pooled results from two phase 3 trials (LIBERTY-PN PRIME and PRIME2)
British Journal of Dermatology2024-08-01
P082 Dupilumab is efficacious in patients above and below 60 years old with prurigo nodularis: pooled results from two phase III trials (LIBERTY-PN PRIME and PRIME2)
British Journal of Dermatology2024-06-28
Responder analysis using clinically meaningful thresholds: Post hoc analyses from randomized dupilumab clinical trials in patients with prurigo nodularis
Journal of the European Academy of Dermatology and Venereology2024-05-246 citations
Validation of a scoring algorithm for the clinician‐reported outcome tool ‘prurigo activity and severity (<scp>PAS</scp>)’ based on clinical studies of dupilumab in adults with prurigo Nodularis
Journal of the European Academy of Dermatology and Venereology2024-04-023 citations
Estimating meaningful change thresholds for Skin Pain‐Numeric Rating Scale, Sleep‐Numeric Rating Scale and Dermatology Life Quality Index in patients with prurigo nodularis
Journal of the European Academy of Dermatology and Venereology2024-02-086 citations
510 - Dupilumab is efficacious in patients with prurigo nodularis regardless of stable use of topical corticosteroids and topical calcineurin inhibitors: pooled results from two phase 3 trials (LIBERTY-PN PRIME and PRIME2)
British Journal of Dermatology2024-02-011 citations
506 - Dupilumab is efficacious in patients with prurigo nodularis regardless of history of atopic comorbidities: pooled results from two phase 3 trials (LIBERTY-PN PRIME and PRIME2)
British Journal of Dermatology2024-02-01
P71 Dupilumab improves patient-reported itch and other signs and symptoms of disease in adults with prurigo nodularis (LIBERTY-PN PRIME and PRIME2)
British Journal of Dermatology2023-06-01
Dupilumab in patients with prurigo nodularis: two randomized, double-blind, placebo-controlled phase 3 trials
Nature Medicine2023-05-01193 citations
Maintenance of response to dupilumab in prurigo nodularis: A retrospective cohort study
JAAD International2023-02-247 citations
344 Dupilumab significantly improves itch and skin lesions in patients with prurigo nodularis: pooled results from two phase 3 trials (LIBERTY-PN PRIME and PRIME2)
British Journal of Dermatology2023-01-254 citations
341 Dupilumab improves itch and skin lesions in adults with prurigo nodularis regardless of prior use of immunosuppressants or phototherapy: post-hoc results from PRIME and PRIME2 clinical trials
British Journal of Dermatology2023-01-25

2 more papers not shown